# South Korea Acute Pancreatitis Market

> South Korea Acute Pancreatitis Market Research Report: By Cause (Gallstones, Alcohol, Others), By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Others), By Diagnosis (Imaging Tests, Laboratory Tests) andBy End-User (Hospitals, Clinics, Others)- Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.84%
- **2018:** $ 117.6 Million
- **2024:** $ 0.16 Billion
- **2035:** $ 0.56 Billion
- **Key Players:** Samsung Biologics (KR), Celltrion (KR), Hanmi Pharmaceutical (KR), LG Chem (KR), Daewoong Pharmaceutical (KR), SK Biopharmaceuticals (KR), Korea United Pharm (KR), Medytox (KR)

**Report ID:** MRFR/HC/54717-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** May 12, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-acute-pancreatitis-market-56483

---

## Market Summary

**South Korea Acute Pancreatitis Market Overview****:**

**As per MRFR analysis, the South Korea Acute Pancreatitis Market Size was estimated at 117.6 (USD Million) in 202****4****.************The South Korea Acute Pancreatitis Market Industry is expected to grow from 125.8(USD Million) in 202****5****to 437.2 (USD Million) by 2035. The South Korea Acute Pancreatitis Market CAGR (growth rate) is expected to be around 11.991% during the forecast period (2025 - 2035).**

**Key South Korea Acute Pancreatitis Market Trends Highlighted**

The South Korea Acute Pancreatitis Market is witnessing significant trends driven by the increasing prevalence of lifestyle-related diseases and growing awareness about digestive health. An uptick in cases of acute pancreatitis is often linked to unhealthy dietary habits, obesity, and high alcohol consumption, which are pressing concerns in South Korea. Consequently, healthcare systems are focusing on improved diagnostics and treatment options for this condition. Key market drivers include government initiatives aimed at enhancing healthcare infrastructure and research investments into innovative treatment methodologies. Such efforts are reflected in the reformation of the National Health Insurance System to cover advanced medical procedures.Opportunities exist for pharmaceutical and biotechnology companies to develop specialized treatments tailored specifically for acute pancreatitis, given the unique dietary and health patterns of the South Korean population. There is growing interest in natural and herbal medicines, driven by traditional medicine practices and a shifted perception towards holistic approaches to health. This trend encourages companies to explore alternative treatments that could complement conventional therapies. In recent times, the South Korean healthcare market also towards a more patient-centered model. The rise of digital health technologies and telemedicine is reshaping how patients access care for digestive disorders, including acute pancreatitis.With the accelerated adoption of electronic health records, healthcare providers can offer personalized treatment plans and track patients more effectively. Additionally, educational campaigns focused on awareness and prevention are becoming more common, driving the demand for better healthcare services and enhancing patient engagement in managing their health. Overall, these trends signify a proactive shift in how acute pancreatitis is approached within the South Korean healthcare landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Acute Pancreatitis Market Drivers**

Increasing Incidence of Acute Pancreatitis

The South Korea Acute Pancreatitis Market Industry is poised for growth due to the rising incidence of acute pancreatitis in the country. Recent data from the Ministry of Health and Welfare of South Korea indicates that cases of acute pancreatitis have increased by approximately 15% over the past decade, with nearly 20,000 annual hospital admissions attributable to this condition. This significant rise highlights a growing patient population, thereby increasing the demand for effective treatment options and healthcare services related to acute pancreatitis.Moreover, large healthcare organizations, including the Korea Disease Control and Prevention Agency, have pointed out that alcohol consumption and other dietary habits are also contributing to this increase. This remarkable fact is causing a high concern in developing more sophisticated therapeutic and management solutions specifically tailored to tackle this condition, thereby stirring investment and innovation in the South Korea Acute Pancreatitis Market Industry.

Technological Advancements in Diagnostic Procedures

Advancements in diagnostic technologies are a major driver for the South Korea Acute Pancreatitis Market. The introduction of minimally invasive techniques and enhanced imaging technologies, such as Magnetic Resonance Imaging (MRI) and Endoscopic Ultrasound (EUS), has improved diagnosis rates. According to the Korean Society of Gastroenterology, the adoption of these advanced diagnostic methods has resulted in a 25% increase in the timely diagnosis of acute pancreatitis, which facilitates quicker treatment interventions.With noted investments in Research and Development from leading healthcare organizations and universities in South Korea, the accuracy and speed of diagnostics continue to improve, thus driving growth in the overall market as better diagnostic capabilities lead to a higher demand for effective treatment options.

Government Initiatives for Healthcare Improvement

The South Korean government has implemented various initiatives aimed at improving healthcare standards and access, which will positively impact the South Korea Acute Pancreatitis Market Industry. The Korean government’s 'Healthy Korea 2030' initiative aims to reduce lifestyle-related diseases, including those leading to acute pancreatitis, by promoting healthier lifestyles and facilitating access to medical care. As part of this initiative, investment in healthcare infrastructure is projected to reach over USD 10 billion by 2025, which will enhance facilities dedicated to gastrointestinal health.This substantial investment, driven by public health policy, is expected to facilitate better management of acute pancreatitis cases, ultimately propelling market growth as more patients receive prompt and efficient care.

**South Korea Acute Pancreatitis Market Segment Insights****:**

**Acute Pancreatitis Market Cause Insights**

The South Korea Acute Pancreatitis Market, particularly focusing on the Cause segment, has shown significant dynamics in recent years. Acute pancreatitis primarily arises from conditions such as gallstones, alcohol consumption, and other factors, each playing a crucial role in the disease's prevalence. Gallstones are known to be one of the leading causes, accounting for a considerable portion of acute pancreatitis cases, as they can block the pancreatic duct, leading to inflammation. This causes not only discomfort but can also result in serious complications if left untreated.Alcohol is another major contributor, with high alcohol intake identified as a frequent risk factor among the population, particularly due to lifestyle habits in South Korea. As the consumption rates fluctuate, so does the incidence of alcohol-induced acute pancreatitis, which makes monitoring essential for public health initiatives. Moreover, the "Others" category encompasses a range of less common causes, including specific medications, genetic disorders, and metabolic conditions, which, although less prevalent, warrant attention due to their complexity and the challenges they pose in treatment and prevention.The South Korea Acute Pancreatitis Market segmentation reflects a growing awareness of these causes, driving demand for effective therapeutic solutions and unique management strategies. As healthcare providers and researchers focus on understanding these contributing factors, there's potential for improved patient outcomes through targeted intervention programs. The South Korean healthcare sector is increasingly recognizing the need for educational campaigns and preventive measures to reduce instances of acute pancreatitis stemming from these causes, ensuring a more informed public while paving the way for advanced treatments.The market growth in this segment is expected to continue as healthcare initiatives prioritize addressing the direct links between lifestyle choices and health outcomes.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Acute Pancreatitis Market Treatment Insights**

The Treatment segment of the South Korea Acute Pancreatitis Market demonstrates significant growth potential as healthcare systems increasingly focus on providing effective solutions for this condition. Intravenous Fluid therapies play a crucial role in patient management, ensuring adequate hydration and electrolyte balance, which is vital for recovery. Nutritional Support is becoming increasingly recognized for its importance in promoting healing and mitigating complications, thus driving demand for specialized nutritional products. Analgesics are essential for pain management, a primary concern in acute pancreatitis, ensuring patient comfort and enhancing recovery outcomes.Endoscopic Retrograde Cholangiopancreatography (ERCP) is a minimally invasive procedure that has gained popularity for its efficiency in treating complications arising from acute pancreatitis, notably obstructive jaundice. Collectively, these treatment modalities reflect a growing trend in South Korea towards personalized and effective patient care strategies aimed at improving patient outcomes while addressing the unique challenges presented by this condition. As a result, stakeholders in the South Korea Acute Pancreatitis Market are likely to prioritize innovation and research in these areas to cater to the rising demand for effective treatment options.

**Acute Pancreatitis Market Diagnosis Insights**

The Diagnosis segment of the South Korea Acute Pancreatitis Market plays a crucial role in patient management and treatment outcomes, showcasing a robust framework that consists primarily of Imaging Tests and Laboratory Tests. Imaging Tests, including ultrasound and computed tomography (CT), are pivotal for accurately visualizing pancreatic conditions and diagnosing acute pancreatitis, fostering valuable information for healthcare professionals. Meanwhile, Laboratory Tests, such as serum amylase and lipase assays, provide essential biochemical insights, indicating the presence and severity of the condition.The increasing prevalence of risk factors associated with acute pancreatitis, such as gallstones and alcohol consumption, drives a growing demand for effective diagnostic solutions. Moreover, advancements in diagnostic technology have strengthened the efficacy and speed of diagnoses, further enhancing patient care. As South Korea emphasizes healthcare innovation, the integration of artificial intelligence and machine learning in diagnostic processes has the potential to revolutionize the accuracy and efficiency of these tests, thereby improving clinical decision-making.Such developments underscore the significance and dominance of the Diagnosis segment in addressing acute pancreatitis, reflecting a proactive approach toward patient management and overall health outcomes in the region.

**Acute Pancreatitis Market End-User Insights**

The South Korea Acute Pancreatitis Market, particularly within the End-User segment, showcases a diverse landscape driven by the increasing prevalence of acute pancreatitis in the region. Hospitals are key players, as they provide comprehensive care and advanced treatment options for patients, reflecting their significant role in patient management. Clinics also contribute notably, offering outpatient services that cater to early-stage diagnosis and follow-up care, thus improving patient outcomes. Other facilities play a crucial role in the overall healthcare provision, especially in specialized settings where patients may seek alternative treatment approaches.The growing awareness about early detection and intervention in acute pancreatitis further fuels growth in this segment, supported by government initiatives aimed at improving healthcare access and quality. Moreover, advancements in medical technology and treatment methodologies present substantial opportunities for innovation in these end-user spaces. As the healthcare system in South Korea continues to evolve, the specific needs of different segments within the End-User category are likely to shape future market trends and growth initiatives in the South Korea Acute Pancreatitis Market.

**South Korea Acute Pancreatitis Market Key Players and Competitive Insights****:**

The South Korea Acute Pancreatitis Market has been experiencing a steady growth trajectory fueled by increasing awareness regarding the treatment and management of pancreatic disorders. The competitive landscape is characterized by a myriad of players engaged in providing innovative therapies and solutions. With the rising prevalence of acute pancreatitis cases and evolving healthcare policies aiming at enhancing patient outcomes, companies are vying to establish their foothold by offering diverse therapeutic options. Market dynamics are shaped by various factors, including technological advancements in treatment methodologies, regulatory approvals, and the heightened focus on research and development. The competitive insights highlight the market's potential for future growth, underscoring the urgency for companies to comprehend and adapt to the continually changing environment.Korean Cell Therapy has positioned itself as a formidable player in the South Korea Acute Pancreatitis Market by focusing on innovative stem cell-based treatments. The company has built a strong reputation through its commitment to research and development, leading to the creation of advanced therapeutic solutions designed specifically for addressing acute pancreatitis. The strengths of Korean Cell Therapy lie in its robust product pipeline and partnerships with leading research institutions, which enhance its credibility in the market. The company’s deep understanding of patient needs and its commitment to delivering high-quality therapeutic options allow it to engage effectively with healthcare professionals and stakeholders, reinforcing its position in this specialized field. The focus on cutting-edge technology and personalized treatment solutions has enabled Korean Cell Therapy to stay ahead of market trends, contributing to its competitive edge.Celltrion is another significant entity in the South Korea Acute Pancreatitis Market, recognized for its innovative biopharmaceutical products. The company has developed key products that cater to the treatment of acute pancreatitis, particularly focusing on enzyme replacement therapies that help mitigate patient suffering. Its market presence is bolstered by a diverse portfolio of therapeutic agents designed to target various aspects of pancreatic health. Celltrion's strengths also extend to its strong research capabilities and commitment to quality, which is evident in its stringent manufacturing processes. Additionally, the company has engaged in strategic mergers and acquisitions, further solidifying its position in the South Korean healthcare ecosystem. These initiatives not only enhance Celltrion's market armamentarium but also facilitate its capacity to deliver high-quality products efficiently, ultimately benefiting patients grappling with acute pancreatitis and enhancing healthcare outcomes across the region.

**Key Companies in the South Korea Acute Pancreatitis Market Include:**

Korean Cell Therapy

Celltrion

Medytox

SK Biopharmaceuticals

DongA ST

Korea Pharmaceutical

JW Pharmaceutical

LG Chem

Hugel

Daewoong Pharmaceutical

Hanmi Pharm

Eagle Pharm

Samsung Biologics

Genexine

**South Korea Acute Pancreatitis Market Industry Developments**

_The South Korea Acute Pancreatitis Market has experienced notable recent developments. There has been a growing focus on innovative therapeutic strategies driven by companies like Korean Cell Therapy and Celltrion, which are advancing their Research and Development initiatives to enhance treatment efficacy for acute pancreatitis. Medytox and SK Biopharmaceuticals are reportedly expanding collaboration efforts, aiming to leverage cutting-edge biotechnology in their drug development processes. In September 2023, DongA ST successfully launched a new treatment formulation specifically targeting acute pancreatitis, signaling a robust commitment to addressing unmet medical needs.____Additionally, in March 2023, Korea Pharmaceutical and JW Pharmaceutical announced a strategic partnership to co-develop a novel therapeutic agent for the condition. Significant growth has been noted in the market valuation of companies such as LG Chem and Daewoong Pharmaceutical, attributed to increased demand for effective interventions. Moreover, recent major happenings include the approval of several investigational drugs by Hanmi Pharm and Eagle Pharm, bolstering their market presence. Samsung Biologics and Genexine have also made strides by increasing their production capabilities, responding to the rising prevalence of acute pancreatitis in South Korea,__underlining the market's dynamic landscape in recent years._

**South Korea Acute Pancreatitis Market Segmentation Insights**

**Acute Pancreatitis Market Cause****Outlook**

**Gallstones**

**Alcohol**

**Others**

**Acute Pancreatitis Market Treatment****Outlook**

**Intravenous Fluid**

**Nutritional Support**

**Analgesics**

**Endoscopic Retrograde Cholangiopancreatography (ERCP)**

**Others**

**Acute Pancreatitis Market Diagnosis****Outlook**

**Imaging Tests**

**Laboratory Tests**

**Acute Pancreatitis Market End-User****Outlook**

**Hospitals**

**Clinics**

**Others**

****

## Market Drivers

### Rising Incidence of Acute Pancreatitis

The South Korea [Acute Pancreatitis](https://www.marketresearchfuture.com/reports/acute-pancreatitis-market-1565) Market is experiencing growth due to the rising incidence of acute pancreatitis cases. Recent data indicates that the prevalence of this condition has increased, with estimates suggesting that approximately 20 to 30 cases per 100,000 individuals are diagnosed annually. This trend is likely influenced by lifestyle factors such as increased alcohol consumption and dietary changes. As the population ages, the incidence may further escalate, prompting healthcare providers to seek effective treatment options. Consequently, this rising incidence drives demand for innovative therapies and management strategies within the South Korea Acute Pancreatitis Market, as healthcare systems strive to address the growing burden of this condition.

### Increased Research and Development Activities

The South Korea Acute Pancreatitis Market is bolstered by increased research and development activities focused on understanding the pathophysiology of acute pancreatitis. Academic institutions and pharmaceutical companies are investing in studies aimed at identifying novel biomarkers and therapeutic targets. Recent collaborations between universities and biotech firms have led to promising developments in drug discovery and clinical trials. For instance, research into the role of gut microbiota in acute pancreatitis is gaining traction, potentially leading to innovative treatment strategies. As these R&D efforts progress, they are likely to yield new therapies and diagnostic tools, thereby driving growth in the South Korea Acute Pancreatitis Market and improving patient care.

### Government Initiatives and Healthcare Policies

The South Korea Acute Pancreatitis Market is significantly influenced by government initiatives aimed at improving healthcare outcomes. The South Korean government has implemented various policies to enhance the management of gastrointestinal diseases, including acute pancreatitis. These initiatives often focus on increasing funding for research, improving access to healthcare services, and promoting public awareness campaigns. For instance, the National Health Insurance Service has expanded coverage for diagnostic procedures and treatments related to acute pancreatitis, which may lead to increased patient access to necessary care. Such supportive policies are likely to foster growth in the South Korea Acute Pancreatitis Market, as they encourage the development and adoption of advanced treatment modalities.

### Technological Advancements in Treatment Options

The South Korea Acute Pancreatitis Market is witnessing a surge in technological advancements that enhance treatment options for patients. Innovations in minimally invasive surgical techniques and endoscopic interventions have revolutionized the management of acute pancreatitis. For example, the introduction of endoscopic retrograde cholangiopancreatography (ERCP) has improved the ability to diagnose and treat complications associated with acute pancreatitis. Furthermore, the development of novel pharmacological agents targeting inflammation and pain management is expected to expand treatment possibilities. As these technologies become more widely adopted, they are likely to drive growth in the South Korea Acute Pancreatitis Market, providing patients with more effective and less invasive treatment alternatives.

### Growing Demand for Specialized Healthcare Services

The South Korea Acute Pancreatitis Market is experiencing a growing demand for specialized healthcare services tailored to the management of acute pancreatitis. As awareness of the condition increases, patients are seeking out specialized clinics and healthcare providers with expertise in gastrointestinal disorders. This trend is reflected in the establishment of dedicated pancreatitis treatment centers across the country, which offer comprehensive care and multidisciplinary approaches. Additionally, the rise of telemedicine has facilitated access to specialized consultations, allowing patients to receive expert advice without geographical constraints. This shift towards specialized care is likely to enhance patient outcomes and drive growth in the South Korea Acute Pancreatitis Market, as more individuals seek targeted treatment options.

## Future Outlook

The South Korea Acute Pancreatitis Market is projected to grow at 11.84% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring Investment in AI-driven diagnostic tools for early detection Expansion of specialized dietary management programs for patients

By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment methodologies and patient care.

## Segment Insights

### By Type of Acute Pancreatitis: Acute Edematous Pancreatitis (Largest) vs. Acute Necrotizing Pancreatitis (Fastest-Growing)

In the South Korea Acute Pancreatitis Market, the segment distribution highlights Acute Edematous Pancreatitis as the largest type, capturing significant market share. Acute Necrotizing Pancreatitis follows closely behind, characterized by its increasingly relevant presence amidst rising occurrence rates. Acute Hemorrhagic and Acute Recurrent Pancreatitis occupy smaller shares, revealing a more niche focus on acute cases with recurrent episodes and complications arising from hemorrhage and necrosis. The growth of Acute Edematous Pancreatitis is bolstered by an increasing prevalence of gallstone-related pancreatitis and alcohol-induced cases. In contrast, Acute Necrotizing Pancreatitis is emerging as the fastest-growing segment due to rising awareness, improved diagnostic practices, and targeted treatment protocols. Healthcare innovations and patient management strategies are further driving these trends, facilitating better outcomes and understanding of pancreatitis types in South Korea.

Acute Edematous Pancreatitis (Dominant) vs. Acute Recurrent Pancreatitis (Emerging)

Acute Edematous Pancreatitis stands as the dominant segment within the South Korea Acute Pancreatitis Market, characterized by its less severe clinical course compared to other types. It is primarily associated with less complex treatment requirements, making it the most manageable form of pancreatitis. In contrast, Acute Recurrent Pancreatitis, while smaller in market share, is increasingly recognized as an important emerging segment. This type often presents with repeated hospitalizations and ongoing treatment, emphasizing the need for effective management strategies. Factors contributing to the rising awareness of Acute Recurrent Pancreatitis include improved patient education and healthcare access, which are crucial for long-term management and prevention of exacerbations.

### By Diagnosis Method: Imaging Techniques (Largest) vs. Blood Tests (Fastest-Growing)

The South Korea Acute Pancreatitis Market showcases a varied distribution among diagnosis methods. Imaging Techniques hold the largest share, primarily due to their effectiveness in visualizing the pancreas and detecting inflammation. Blood Tests, while currently smaller in share, have rapidly gained traction owing to their accessibility and efficiency in providing quick results. Endoscopic Procedures and Biopsy, although essential, represent niche segments compared to the major techniques, contributing less significantly to overall market dynamics. The growth trends in the Diagnosis Method segment are driven by advancements in technology and increasing awareness regarding acute pancreatitis. Imaging Techniques are seeing enhancements in imaging quality and minimally invasive functionalities, hence solidifying their leading position. Meanwhile, Blood Tests are emerging as the fastest-growing method due to innovations in biomarker identification and portable testing solutions. As healthcare providers aim for timely diagnosis, these methods are continually evolving to meet clinical needs and patient expectations.

Imaging Techniques (Dominant) vs. Endoscopic Procedures (Emerging)

Imaging Techniques remain the dominant diagnostic method within the South Korea Acute Pancreatitis Market due to their superior capability to visualize pancreatic conditions accurately. These techniques, such as CT scans and MRI, are vital for diagnosing the severity of pancreatitis and planning subsequent treatment. Conversely, Endoscopic Procedures, which involve inspecting the pancreas through endoscopy, are emerging as a valuable alternative. They offer the potential for intervention during the diagnostic phase, such as obtaining tissue samples for further analysis. While still developing in prevalence, Endoscopic Procedures are gaining attention for their precision and ability to address complications, thus representing a growing interest in integrative diagnostic approaches.

### By Treatment Approach: Medical Management (Largest) vs. Surgical Intervention (Fastest-Growing)

In the South Korea Acute Pancreatitis Market, the treatment approach is fundamentally divided into four key segments: Medical Management, Surgical Intervention, Nutritional Support, and Endoscopic Therapy. Medical Management holds the largest share of the market, reflecting its established role in treating acute pancreatitis, focusing on medication and supportive care. In contrast, Surgical Intervention is rapidly gaining ground, positioning itself as the fastest-growing segment due to advances in surgical techniques and the increasing recognition of its necessity in severe cases.

Medical Management (Dominant) vs. Surgical Intervention (Emerging)

Medical Management is characterized by a focus on conservative treatment methods, including pharmacological therapies aimed at pain relief and inflammation reduction. This approach has traditionally dominated the South Korean market due to its low cost and effectiveness in less severe cases of acute pancreatitis. Meanwhile, Surgical Intervention is emerging rapidly, driven by advancements in minimally invasive techniques and a growing awareness of the need for early intervention in complicated cases. These two segments exhibit contrasting characteristics, with Medical Management being more conservative and Surgical Intervention being proactive, collectively shaping treatment protocols for health professionals.

### By Patient Demographics: Age Group (Largest) vs. Lifestyle Factors (Fastest-Growing)

In the South Korea Acute Pancreatitis Market, patient demographics exhibit distinct divisions across various parameters. The largest age group observed is between 50-70 years, where patients tend to exhibit higher prevalence due to lifestyle diseases and comorbid conditions. This demographic holds significant shares within the market, highlighting its critical role in diagnosis and treatment patterns. Alternatively, lifestyle factors, notably obesity and increased alcohol intake, are swiftly gaining attention as they represent the fastest-growing segment among younger populations, leading to a rise in acute pancreatitis cases.

Age Group (Dominant) vs. Lifestyle Factors (Emerging)

The age group of 50-70 years serves as the dominant demographic for acute pancreatitis in South Korea, characterized by a higher incidence linked to chronic health issues. This cohort tends to seek medical intervention more frequently, prompting healthcare trends centered around age-specific treatments. Conversely, lifestyle factors are emerging as a critical influence in the younger population, particularly due to the rising rates of obesity and unhealthy dietary habits. This shift illustrates a change in the disease profile, prompting healthcare providers to adapt treatment methodologies to align with these emerging lifestyle-related risk factors.

## Competitive Benchmarking

The South Korea Acute Pancreatitis Market is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Samsung Biologics (KR), Celltrion (KR), and Hanmi Pharmaceutical (KR) are actively engaged in enhancing their operational focus through research and development, aiming to introduce novel therapeutic solutions. Samsung Biologics (KR) has positioned itself as a leader in biopharmaceutical manufacturing, emphasizing the importance of high-quality production capabilities. Meanwhile, Celltrion (KR) is leveraging its expertise in biosimilars to expand its product portfolio, which is crucial for addressing the growing demand for effective treatments in this market. Hanmi Pharmaceutical (KR) is also focusing on strategic collaborations to enhance its research capabilities, thereby contributing to a dynamic competitive environment that fosters innovation and growth.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing their supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive advancements in treatment options and improve patient outcomes. This competitive structure suggests that while there are numerous participants, the leading firms are likely to dominate through their strategic initiatives and operational efficiencies.
In January 2026, LG Chem (KR) announced a partnership with a leading research institution to develop a novel drug delivery system aimed at improving the efficacy of treatments for acute pancreatitis. This strategic move is indicative of LG Chem's commitment to innovation and its recognition of the need for advanced therapeutic solutions. By collaborating with academic institutions, LG Chem (KR) is not only enhancing its research capabilities but also positioning itself to be at the forefront of emerging treatment modalities.
In December 2025, Daewoong Pharmaceutical (KR) launched a new clinical trial for a promising drug candidate targeting acute pancreatitis. This initiative underscores Daewoong's focus on expanding its therapeutic offerings and addressing unmet medical needs in the market. The successful completion of this trial could potentially lead to a breakthrough treatment, thereby enhancing the company's competitive positioning and market share.
In November 2025, SK Biopharmaceuticals (KR) entered into a strategic alliance with a global pharmaceutical company to co-develop a new therapeutic agent for acute pancreatitis. This collaboration is likely to enhance SK Biopharmaceuticals' research capabilities and accelerate the development timeline for new treatments. Such alliances are becoming increasingly common as companies seek to pool resources and expertise to navigate the complexities of [drug development](https://www.marketresearchfuture.com/reports/drug-development-market-66529).
As of February 2026, the competitive trends in the South Korea Acute Pancreatitis Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are playing a pivotal role in shaping the current landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition is likely to redefine how companies position themselves in the market, emphasizing the importance of developing cutting-edge solutions that meet the evolving needs of patients.

## Recent News & Developments

_The South Korea Acute Pancreatitis Market has experienced notable recent developments. There has been a growing focus on innovative therapeutic strategies driven by companies like Korean Cell Therapy and Celltrion, which are advancing their Research and Development initiatives to enhance treatment efficacy for acute pancreatitis. Medytox and SK Biopharmaceuticals are reportedly expanding collaboration efforts, aiming to leverage cutting-edge biotechnology in their drug development processes. In September 2023, DongA ST successfully launched a new treatment formulation specifically targeting acute pancreatitis, signaling a robust commitment to addressing unmet medical needs.__Additionally, in March 2023, Korea Pharmaceutical and JW Pharmaceutical announced a strategic partnership to co-develop a novel therapeutic agent for the condition. Significant growth has been noted in the market valuation of companies such as LG Chem and Daewoong Pharmaceutical, attributed to increased demand for effective interventions. Moreover, recent major happenings include the approval of several investigational drugs by Hanmi Pharm and Eagle Pharm, bolstering their market presence. Samsung Biologics and Genexine have also made strides by increasing their production capabilities, responding to the rising prevalence of acute pancreatitis in South Korea,__underlining the market's dynamic landscape in recent years._

## Report Scope

Report Scope:

| Report Attribute/Metric Source: | Details |
| --- | --- |
| MARKET SIZE 2018 | 117.6(USD Million) |
| MARKET SIZE 2024 | 125.8(USD Million) |
| MARKET SIZE 2035 | 437.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.991% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Korean Cell Therapy, Celltrion, Medytox, SK Biopharmaceuticals, DongA ST, Korea Pharmaceutical, JW Pharmaceutical, LG Chem, Hugel, Daewoong Pharmaceutical, Hanmi Pharm, Eagle Pharm, Samsung Biologics, Genexine |
| SEGMENTS COVERED | Cause, Treatment, Diagnosis, End-User |
| KEY MARKET OPPORTUNITIES | Growing prevalence of acute pancreatitis, Advancements in diagnostic technologies, Innovative treatment solutions development, Increased healthcare funding and investments, Rising awareness and education initiatives |
| KEY MARKET DYNAMICS | Increasing prevalence of pancreatitis, Advances in treatment options, Growing awareness and diagnosis, Rising healthcare expenditure, Aging population demographics |
| COUNTRIES COVERED | South Korea |

## Frequently Asked Questions

**Q: What is the current valuation of the South Korea Acute Pancreatitis Market?**
A: As of 2024, the market valuation was 0.164 USD Billion.

**Q: What is the projected market size for the South Korea Acute Pancreatitis Market by 2035?**
A: The market is projected to reach 0.563 USD Billion by 2035.

**Q: What is the expected CAGR for the South Korea Acute Pancreatitis Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 11.84%.

**Q: Which companies are the key players in the South Korea Acute Pancreatitis Market?**
A: Key players include Samsung Biologics, Celltrion, Hanmi Pharmaceutical, LG Chem, Daewoong Pharmaceutical, SK Biopharmaceuticals, Korea United Pharm, and Medytox.

**Q: What are the main types of acute pancreatitis and their market valuations?**
A: The market valuations for types include Acute Edematous Pancreatitis at 0.227 USD Billion and Acute Necrotizing Pancreatitis at 0.158 USD Billion.

**Q: How does the market for diagnostic methods in acute pancreatitis break down?**
A: By diagnosis method, Imaging Techniques are valued at 0.227 USD Billion, while Blood Tests are at 0.158 USD Billion.

**Q: What treatment approaches are prevalent in the South Korea Acute Pancreatitis Market?**
A: Medical Management leads with a valuation of 0.227 USD Billion, followed by Surgical Intervention at 0.158 USD Billion.

**Q: What demographic factors influence the South Korea Acute Pancreatitis Market?**
A: Comorbid Conditions are valued at 0.194 USD Billion, indicating a significant influence on the market.

**Q: How does the market for acute pancreatitis treatment compare across different patient demographics?**
A: The market segments by patient demographics show Age Group at 0.158 USD Billion and Lifestyle Factors at 0.088 USD Billion.

**Q: What trends are expected in the South Korea Acute Pancreatitis Market by 2035?**
A: The market is likely to expand significantly, driven by advancements in treatment and increasing awareness.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-acute-pancreatitis-market-56483*